Innovative Wearable and Open Platform for a Personalized Treatment of Stress

Informations projet

XANA

N° de convention de subvention: 781703

DOI

10.3030/781703

Projet clôturé

Date de signature de la CE 17 Juillet 2017

Date de début 1 Août 2017

Date de fin 30 Novembre 2017

Financé au titre de

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)

Coût total

€ 71 429,00

Contribution de l’UE

€ 50 000,00

Coordonné par

WALDEN MEDICAL NEURO DIGITAL THERAPIES, S.L.
Spain

Periodic Reporting for period 1 - XANA (Innovative Wearable and Open Platform for a Personalized Treatment of Stress)

Période du rapport: 2017-08-01 au 2017-11-30

Résumé du contexte et des objectifs généraux du projet

Walden Medical® has been created aiming to design, develop and commercialize XANA product (device and platform): a personalized and non-invasive neurostimulation treatment for stress relief. Previous R&D project results, where three of the founders were involved, showed the potential and technical viability required for boosting the creation of the company.
The initial goal was to develop a non-invasive system to stimulate parasympathetic nervous system activity and thus maintain homeostasis, compensating for the excessive activation of the sympathetic nervous system due to the response to stressful stimuli.
After several anatomical and physiological studies, we designed an ergonomic and usable wearable neurostimulator operated from a software app for smartphone and capable of electrically stimulating the Auricular Brach of the Vagus Nerve.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

Once the design was completed, we developed the prototype for a Minimum Viable Product (MVP) that consists of an auricular electrical neurostimulator connected by Bluetooth to our software app.
This development process served also to determine the functional properties and specifications for the optimization of the XANA MVP product. The improvements to get a more user-friendly, efficient and customized product (XANA BCAS) are:
Bilateral: one stimulator for each ear, to improve efficiency.
Customized: An scan of the user´s auditory canals will be used to build the anatomically customized stimulators.
Autonomous: the stimulators can operate without the smartphone.
SMART: implementation of both electrical and mechanical stimulation and music therapy.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

Since stress affects over 40% of the worldwide population and is linked to over 70% of physical and mental disorders XANA will help to:
1. Solve a high prevalence problem associated to current lifestyle.
2. Prevent other conditions that can be triggered by stress (e.g. anxiety, depression).
3. Decrease the costs of absenteeism and reduce the enormous healthcare system costs, directly caused by stress and indirectly caused by stress-linked-conditions.
4. Reduce the abuse of medication (Benzodiazepines) that causes addiction among other serious side-effects.
5. Develop the mobile Health offer which is the main social trend regarding prevention, monitoring and treatment in the health sector.

xana.png

walden.png